LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription
Zhongjie Lin, Shunjie Xia, Yuelong Liang, Lin Ji, Yu Pan, Jiang Shi, Zhe Wan, Liye Tao, Jiang Chen, Chengping Lin, Xiao Liang, Junjie Xu, Xiujun Cai
Abstract
: Our finding suggested decreased expression of XPO5 prevents maturation of miR-378a-3p, which leaded to the overexpression of IGF-1R and counteracted the effects of sorafenib-induced apoptosis. LXRα was able to activate miRNA-378a-3p transcription in HCC cells and could be a potential combinable treatment strategy with sorafenib to suppress HCC progression.
Topics & Concepts
SorafenibmicroRNAGene silencingCancer researchHepatocellular carcinomaInsulin-like growth factor 1 receptorLiver X receptor alphaBiologyBioinformaticsMedicineTranscription factorInternal medicineGeneReceptorNuclear receptorGeneticsGrowth factorMicroRNA in disease regulationCancer-related molecular mechanisms researchCircular RNAs in diseases